Inozyme Pharma, Inc. — Form D/A
Inozyme Pharma, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2020-06-08. The offering totals $67.4M, of which $67.4M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-06-08
- Form: D/A
- Accession: 0001693011-20-000004
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $67.4M
- Amount sold: $67.4M
- Investors: 12
- Date of first sale: 2018-11-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-326389
Issuer
- Name: Inozyme Pharma, Inc.
- CIK: 0001693011
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 321 Summer Street, BOSTON, MA, 02210
- Phone: 857-330-4340
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Sarah Bhagat | Director | MENLO PARK, CA |
| Axel Bolte | Director | Boston, MA |
| Reinaldo Diaz | Director | Boston, MA |
| Martin Edwards | Director | Boston, MA |
| Rob Hopfner | Director | San Diego, CA |
| Edward Mathers | Director | South San Francisco, CA |
| Lynne Sullivan | Director | Ness Ziona, L3 |
| DOUGLAS TRECO | Director | WINCHESTER, MA |
| Axel Bolte | Executive Officer | Boston, MA |
| Joseph Schlessinger | Director | Woodbridge, CT |
| Joseph Schlessinger | Executive Officer | Woodbridge, CT |
Other filings by this issuer (6)
More